[1] Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides[J]. Eur J Nucl Med Mol Imaging, 2018, 45(5): 846−859. DOI: 10.1007/s00259-018-3947-x.
[2] 李少林, 王荣福, 张永学, 等. 核医学[M]. 8版. 北京: 人民卫生出版社, 2013: 309. Li SL, Wang RF, Zhang YX, et al. Nuclear medicine[M]. 8th ed. Beijing: People's Medical Publishing House, 2013: 309.
[3] Das T, Banerjee S. Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons[J]. Clin Exp Metastasis, 2017, 34(1): 1−10. DOI: 10.1007/s10585-016-9831-9.
[4] Giammarile F, Mognetti T, Resche I. Bone pain palliation with strontium-89 in cancer patients with bone metastases[J]. Q J Nucl Med, 2001, 45(1): 78−83.
[5] 中华医学会核医学分会转移性骨肿瘤治疗工作委员会. 氯化锶[89Sr]治疗转移性骨肿瘤专家共识(2017年版)[J]. 中华核医学与分子影像杂志, 2018, 38(6): 412−415. DOI: 10.3760/cma.j.issn.2095-2848.2018.06.008. The Chinese Society of Nuclear Medicine Working Committee for Treatment of Bone Metastasis. Expert consensus on strontium-89 chloride treatment of bone metastases (2017)[J]. Chin J Nucl Med Mol Imaging, 2018, 38(6): 412−415. DOI: 10.3760/cma.j.issn.2095-2848.2018.06.008.
[6] 姜少军, 谢克基, 蔡岳斌, 等. 前列腺癌骨转移对造血功能的影响[J]. 中国医师进修杂志, 2007, 30(20): 27−28. DOI: 10.3760/cma.j.issn.1673-4904.2007.20.010. Jiang SJ, Xie KJ, Cai YB, et al. Influence of prostatic carcinoma osseous metastasis on the haematogenesis function[J]. Chin J Postgrad Med, 2007, 30(20): 27−28. DOI: 10.3760/cma.j.issn.1673-4904.2007.20.010.
[7] Furubayashi N, Negishi T, Ura S, et al. Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis[J]. Mol Clin Oncol, 2015, 3(1): 257−263. DOI: 10.3892/mco.2014.449.
[8] Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan[J]. Cancer, 1988, 61(1): 195−202. DOI: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y.
[9] 梁树君, 朱广文, 周绍军, 等. SPECT骨显像联合血清碱性磷酸酶检测评估肺癌患者骨转移负荷的价值[J]. 现代肿瘤医学, 2017, 25(13): 2140−2143. DOI: 10.3969/j.issn.1672-4992.2017.13.033. Liang SJ, Zhu GW, Zhou SJ, et al. Evaluate of the value of bone metastases burden by SPECT bone imaging combined with serums alkaline phosphalase in patients with lung cancer[J]. J Mod Oncol, 2017, 25(13): 2140−2143. DOI: 10.3969/j.issn.1672-4992.2017.13.033.
[10] 琚建军, 李云, 郑军荣, 等. 血清碱性磷酸酶在去势抵抗性前列腺癌伴骨转移化疗中的临床意义[J]. 现代医学, 2019, 47(8): 966−969. DOI: 10.3969/j.issn.1671-7562.2019.08.017. Ju JJ, Li Y, Zheng JR, et al. Clinical significance of serum alkaline phosphatase in castration-resistant prostate cancer with chemotherapy for bone metastasis[J]. Mod Med J, 2019, 47(8): 966−969. DOI: 10.3969/j.issn.1671-7562.2019.08.017.
[11] Leeming DJ, Koizumi M, Byrjalsen I, et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(1): 32−38. DOI: 10.1158/1055-9965.EPI-05-0492.
[12] Bayrak SB, Ceylan E, Serter M, et al. The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer[J]. Int J Clin Oncol, 2012, 17(2): 112−118. DOI: 10.1007/s10147-011-0266-7.
[13] 王晶晶, 刘琛, 秦艳茹. 血清碱性磷酸酶、癌胚抗原、糖类抗原19-9联合检测对胃癌骨转移的诊断价值[J]. 癌症进展, 2020, 18(7): 731−734. DOI: 10.11877/j.issn.1672-1535.2020.18.07.23. Wang JJ, Liu C, Qin YR, et al. Diagnostic value of combined detection of serum alkaline phosphatase, carcinoem-bryonic antigen and carbohydrate antigen 19-9 in patients with bone metastasis of gastric cancer[J]. Oncol Prog, 2020, 18(7): 731−734. DOI: 10.11877/j.issn.1672-1535.2020.18.07.23.
[14] Karhade AV, Thio QCBS, Kuverji M, et al. Prognostic value of serum alkaline phosphatase in spinal metastatic disease[J]. Br J Cancer, 2019, 120(6): 640−646. DOI: 10.1038/s41416-019-0407-8.
[15] 胡群超, 俞晓立. 放疗在乳腺癌骨转移中的临床应用进展[J]. 中国癌症杂志, 2016, 26(4): 346−350. DOI: 10.3969/j.issn.1007-3969.2016.04.010. Hu QC, Yu XL. Progress in the clinical use of radiotherapy for bone metastasis in breast cancer[J]. China Oncol, 2016, 26(4): 346−350. DOI: 10.3969/j.issn.1007-3969.2016.04.010.
[16] 黄伟, 钱梦, 谢鸣. 肿瘤放射治疗配合中药增效减毒的临床研究进展[J]. 中国药师, 2017, 20(8): 1374−1381. DOI: 10.3969/j.issn.1008-049X.2017.08.011. Huang W, Qian M, Xie M. Clinical study progress in tumor radiotherapy combined with traditional Chinese medicines with synergistic and attenuated effects[J]. China Pharm, 2017, 20(8): 1374−1381. DOI: 10.3969/j.issn.1008-049X.2017.08.011.
[17] Meng AM, Wang Y, Brown SA, et al. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms[J]. Exp Hematol, 2003, 31(12): 1348−1356. DOI: 10.1016/j.exphem.2003.08.014.
[18] 刘慧云, 刘东胜. 不同分割方式放疗治疗骨转移肿瘤的临床疗效[J]. 肿瘤基础与临床, 2020, 33(2): 107−109. DOI: 10.3969/j.issn.1673-5412.2020.02.004. Liu HY, Liu DS. Clinical efficacy of radiotherapy with different segmentation methods in the treatment of bone metastases[J]. J Basic Clin Oncol, 2020, 33(2): 107−109. DOI: 10.3969/j.issn.1673-5412.2020.02.004.
[19] 左二冬. 放射治疗对肿瘤患者造血系统的影响及其相关发生机制的初步研究[D]. 苏州: 苏州大学, 2016. Zuo ED. Preliminary study of impacts of radiation therapy on hematopoietic system in cancer patients and its relevant mechanisms[D]. Suzhou: Soochow University, 2016.
[20] 北京医学奖励基金会肺癌青年专家委员会, 中国胸外科肺癌联盟. 肺癌骨转移诊疗专家共识(2019版)[J]. 中国肺癌杂志, 2019, 22(4): 187−207. DOI: 10.3779/j.issn.1009-3419.2019.04.01. The Youth Specialists Committee of Lung Cancer, Beijing Medical Award Foundaton, Chinese Lung Cancer Union. Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2019 version)[J]. Chin J Lung Cancer, 2019, 22(4): 187−207. DOI: 10.3779/j.issn.1009-3419.2019.04.01.
[21] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8): 609−680. DOI: 10.19401/j.cnki.1007-3639.2019.08.009. Chinese Anti-Cancer Association, Committee of Breast Cancer Society. Guidelines for the diagnosis and treatment of breast cancer of the Chinese Anti-Cancer Association (2019 version)[J]. China Oncol, 2019, 29(8): 609−680. DOI: 10.19401/j.cnki.1007-3639.2019.08.009.
[22] 于林江. TE方案新辅助化疗在乳腺癌治疗中的应用效果及作用价值[J]. 数理医药学杂志, 2020, 33(2): 164−166. DOI: 10.3969/j.issn.1004-4337.2020.02.003. Yu LJ. Application effect and value of TE regimen neoadjuvant chemotherapy in the treatment of breast cancer[J]. J Math Med, 2020, 33(2): 164−166. DOI: 10.3969/j.issn.1004-4337.2020.02.003.
[23] 苏大伟. 吡柔比星为主的联合化疗方案治疗晚期乳腺癌的应用效果观察[J]. 现代诊断与治疗, 2018, 29(10): 1581−1582. DOI: 10.3969/j.issn.1001-8174.2018.10.039. Su DW. Effect of pirorubicin-based combination chemotherapy in advanced breast cancer[J]. Mod Diagn Treat, 2018, 29(10): 1581−1582. DOI: 10.3969/j.issn.1001-8174.2018.10.039.
[24] 罗恩茜, 倪青. 乳腺癌不同方案新辅助化疗后对粒细胞减少的影响及处理[J]. 重庆医学, 2018, 47(7): 971−974. DOI: 10.3969/j.issn.1671-8348.2018.07.030. Luo EQ, Ni Q. Effect of neoadjuvant chemotherapy on granulocytopenia of breast cancer and its management[J]. Chongqing Med, 2018, 47(7): 971−974. DOI: 10.3969/j.issn.1671-8348.2018.07.030.
[25] 石远凯, 孙燕, 于金明, 等. 中国晚期原发性肺癌诊治专家共识(2016年版)[J]. 中国肺癌杂志, 2016, 19(1): 1−15. DOI: 10.3779/j.issn.1009-3419.2016.01.01. Shi YK, Sun Y, Yu JM, et al. China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)[J]. Chin J Lung Cancer, 2016, 19(1): 1−15. DOI: 10.3779/j.issn.1009-3419.2016.01.01.
[26] Hasegawa Y, Miura D, Kitamura C, et al. A randomized phase Ⅱ trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer[J]. Chemotherapy, 2013, 59(5): 346−353. DOI: 10.1159/000362222.
[27] Clément-Zhao A, Auvray M, Aboudagga H, et al. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer[J]. BJU Int, 2018, 121(2): 203−208. DOI: 10.1111/bju.13855.
[28] Shimura Y, Suga Y, Itai S, et al. Comparison of tolerability between 2-weekly and 3-weekly Docetaxel regimen in castration-resistant prostate cancer[J]. Anticancer Res, 2020, 40(8): 4291−4297. DOI: 10.21873/anticanres.14431.
[29] Yano R, Konno A, Watanabe K, et al. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase Ⅱ and Ⅲ trials[J]. Int J Clin Oncol, 2013, 18(1): 96−104. DOI: 10.1007/s10147-011-0349-5.
[30] 石远凯, 孙燕. 临床肿瘤内科手册[M]. 6版. 北京: 人民卫生出版社, 2015: 937. Shi YK, Sun Y. Manual of medical oncology[M]. 6th ed. Beijing: People's Medical Publishing House, 2015: 937.
[31] Papatheofanis FJ, Najib MM. Bone marrow recovery following use of systemic 153Sm-lexidronam and 89Sr-chloride for bone pain palliation after myelosuppressive therapy[J]. Int J Radiat Biol, 2009, 85(5): 448−453. DOI: 10.1080/09553000902818899.
[32] Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial[J]. J Nucl Med, 2002, 43(1): 79−86.
[33] Curtis KK, Adam TJ, Chen SC, et al. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review[J]. Aging Male, 2008, 11(4): 157−161. DOI: 10.1080/13685530802172438.